TFFP: TFF Pharmaceuticals Inc. Forward P/S Multiple
TFF Pharmaceuticals laboratory powder freezing capacities are operating at maximum efficiency for partners. The issuer's future P/S on the GURU.Markets daily chart clearly demonstrates market expectations, where the 22.30 level captures the current state. However, the slow implementation of thin-film technologies is constraining capitalization, while a liquidity deficit and dependence on Big Pharma create serious delisting threats.
Financial and market metric breakdowns for TFF Pharmaceuticals, Inc (TFFP)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt burden and liquidity indicators:
Debt to Equity TFF Pharmaceuticals|TFFP - Long-Term Liabilities to Equity|Short-Term Debt to Capital TFF Pharmaceuticals|TFFP - Aggregate Debt Obligations|Debts to Book Capitalization TFF Pharmaceuticals, Inc|TFFP - Company Long-Term Debts|Company Short-Term Debt TFF Pharmaceuticals|Quick Liquidity tffpharma.com
- financial results and valuation multiples details:
TFFP - Net Income|Projected Future Earnings TFF Pharmaceuticals|TFFP - P/E Multiple|Forward P/E Multiple TFF Pharma|TFFP - Price/Earnings to Growth Multiple|EV/EBITDA Multiple TFF Pharmaceuticals, Inc|TFFP - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months TFF Pharmaceuticals|TFFP - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months tffpharma.com|TFFP - Net earnings per one share growth for the current year|Earnings growth forecast for next year TFF Pharmaceuticals
- sales volume and revenue information:
Summary company analysis:TFF Pharmaceuticals, Inc. TFFP
For TFF Pharmaceuticals, which is scaling drug delivery via thin films, this metric reflects the long-term value of the business relative to expected revenue streams. By analyzing the projected P/S ratio, an investor assesses market capitalization through the lens of future sales in the inhalation drug niche, enabling the timely identification of trend reversals and the protection of capital from depreciation during periods of stagnation.
Competitors of TFF Pharmaceuticals
Haleon - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio KVUE (Kenvue Inc)|Verona Pharma Corp - Forward P/S Multiple|Future Price to Revenue MENS|LGND: Forward P/S Multiple|Future Price to Revenue AMRX (amneal.com)|Forward Price-to-Revenue Multiple PRGO|ALVO: Forward Price to Sales|Price-to-Projected Revenue Ratio Liquidia Technologies (LQDA)|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|Forward Price to Sales MNKD|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|PCRX - Forward P/S Multiple|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|Theravance Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio Aquestive Therapeutics|Forward Price-to-Revenue Multiple scPharma (SCPH)|Forward P/S Multiple TECX|Forward P/S Multiple Tonix Pharma (TNXP)|Forward P/S Multiple SXTC (China SXT Pharmaceuticals, Inc.)|EPRX - Forward Price-to-Revenue Multiple|BioHarvest Sciences - Forward P/S Multiple|Market Cap to Future Revenue Ratio invizyne.com|ORMP (oramed.com) - Forward Price-to-Revenue Multiple|Entera Bio (ENTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple HYFT|ABVC (ABVC BioPharma, Inc) - Price to Expected Revenue Ratio|Forward P/S Multiple CPIX|Market Cap to Expected Sales Ratio quantumbiopharma.com|Forward P/S Multiple FGEN (FibroGen)|TELO - Forward Price-to-Revenue Multiple|Rani Therapeutics Inc - Forward P/S Multiple|SNYR - Forward P/S Multiple|rallybio.com (RLYB) - Price-to-Projected Revenue Ratio|LEXX (Lexaria Bioscience Corp.) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Pulmatrix|Pheton (PTHL) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple APM (Aptorum Group Limited)|Price to Expected Revenue Ratio LYRA|Forward P/S Multiple IBO (Impact BioMedical Inc)|TNFA (TNF Pharmaceuticals Inc.) - Future Price to Revenue|cbdMD Corp - Forward P/S Multiple|Future Price to Revenue PRFX|altamiratherapeutics.com (CYTO) - Price-to-Projected Revenue Ratio|Future Price to Revenue LIPO (Lipella Pharma)|Price-to-Projected Revenue Ratio OptiNose, Inc.|pieris.com - Future Price to Revenue|Forward P/S Multiple PROC|PTPI (Petros Pharmaceuticals Inc) - Forward Price to Sales|Forward P/S Multiple QLI (Qilian International Holding Group Limited)|Forward P/S Multiple ACELYRIN Inc. SLRN
